Markets
markets

McDonald’s rises after Q2 sales rebound, as US customers spend more per visit

McDonald’s just posted a US sales rebound in the second quarter — a comeback after a rough start to the year.

Revenue rose 5% year over year to $6.84 billion, beating Wall Street’s $6.7 billion estimate, while adjusted earnings per share came in at $3.19, above the $3.14 expected, according to FactSet.

Global same-store sales climbed 3.8%, topping the 2.6% forecast, aided by 2.5% growth at US locations. That marks a welcome reversal from the first quarter, when the fast-food giant’s US restaurants saw their largest same-store sales decline since early Covid, as budget-conscious customers pulled back on eating out.

After introducing back-to-back menu moves targeting price-sensitive (and chicken-loving) diners, including the May launch of McCrispy Chicken Strips and the June rollout of the $5 Meal Deal, customers have had a lot of protein-packed, snack-sized value options at the golden arches.

But while the value message may have landed, at least in the US, the rebound seems less driven by customers opting for cheaper meals, with McDonald’s saying that the US comparable sales results were primarily driven by positive check growth.

Meanwhile, a nostalgic item could further lift traffic and sales in the current quarter: the burger giant brought back its long-awaited Snack Wrap in July. 

Looking ahead to Q3, McDonald’s plans to test premium sodas aimed at Gen Z, expand late-night hours at US stores, and continue opening new locations globally at a 4% to 5% annual pace.

After introducing back-to-back menu moves targeting price-sensitive (and chicken-loving) diners, including the May launch of McCrispy Chicken Strips and the June rollout of the $5 Meal Deal, customers have had a lot of protein-packed, snack-sized value options at the golden arches.

But while the value message may have landed, at least in the US, the rebound seems less driven by customers opting for cheaper meals, with McDonald’s saying that the US comparable sales results were primarily driven by positive check growth.

Meanwhile, a nostalgic item could further lift traffic and sales in the current quarter: the burger giant brought back its long-awaited Snack Wrap in July. 

Looking ahead to Q3, McDonald’s plans to test premium sodas aimed at Gen Z, expand late-night hours at US stores, and continue opening new locations globally at a 4% to 5% annual pace.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.